

Index

Note: Page numbers of article titles are in **bold face** type.

- ACROSCLEROSIS, 6-7, 246
- Adrenocorticotrophic hormone, 289-290
- Age-specific incidence and mortality in PSS, 16-18
- Alkylating agents, 291-293
- American Rheumatism Association (ARA), 27
- Angiographic abnormalities in kidney, 172-173
- Arrhythmias, 138-139
- Arterial thrombi in kidney, 171-172
- Atrophoderma Pasini-Pierini, 226
- Azotaemia, 169-170

- BLEOMYCIN-INDUCED pseudoscleroderma, 9, 255-256
- Bullous morphea, 236

- CALCERY, 57
- Calcinosis, 54-58
- Calciophylaxis, 56-57
- Captopril, 178, 272-273
- Carcinoid syndrome, 249-250
- Cardiac death, sudden, 140-141
- Cardiac involvement in PSS, **131-149**
 - clinical diagnosis and course of, 145-146
 - clinical perspective, 131-132
 - effect of D-penicillamine on, 282
 - historical perspective, 131
- Cardiovascular system, management of, 270-271, 294
- Chemical-induced scleroderma-like conditions, 9
- Chest pain, 140
- Children, localized scleroderma in, 227-228
- Chlorambucil, 293-295
- Chromosomal abnormalities in PSS, **201-213**
- Chromosomal instabilities—
 - possible causes, 208-211
 - production of breaks, 208-209
 - repair of damage, 209-211
- Classification and nomenclature of PSS, **5-13, 16**
- Colchicine, treatment of PSS with, **294-302**
 - clinical studies with, 295-298
 - effect in localized scleroderma, 299-300
 - effect on collagen metabolism, 295
 - long-term effectiveness of, 298-299
 - side effects of, 300
- Collagen—
 - biosynthesis of, 190, 192-196
 - chromosomal instability and, 206-210
 - content, 61-63, 186-189
 - cross-links of, 189-192
 - degradation of, 196-197
 - effect of colchicine on metabolism of, 295
 - electron microscopic appearance of, 186
 - extractability of, 189
 - genetically distinct types of, 192
 - structure of, 192
- Conduction disturbances, 138-139
- Congestive heart failure, 139-140
- Connective tissue, metabolism of in PSS, **185-200**
- Corticosteroids, 289-290
- CREST syndrome, 6-8, 21-22, 49-54, 58, 61, 64-65
- Cutaneous involvement in PSS, clinical features and pathogenesis of, **49-79**
- Cytogenetic observations—
 - in other connective tissue disorders, 206
 - in PSS patients and families, 202-204

- DATA analysis of SCCS, 35-36
- Demographic features of SCCS, 36-37
- Diagnostic evaluations of SCCS, 32
- Diffuse scleroderma, 49
- Dyspnoea, 152

- ELECTROMYOGRAPHY, 106-107
- Endocardial disease, 141
- Endothelial cell changes in kidney, 171, 173-176
- Eosinophilic fasciitis, 10-11, 244-246
- Epidemiology of PSS, **15-25**
 - methodological considerations, 15-16
- FACIAL hemiatrophy, 221-223

- Familial occurrence PSS, 18-19
 Fasciitis, diffuse, with eosinophilia, 10-11, 244-246
 Fibrin deposits in kidney, 173-176
- GASTROINTESTINAL involvement in PSS, 115-129**
 Gastrointestinal tract—
 effect of chlorambucil on, 294
 effect of D-penicillamine on, 282-283
 management of, 268-269
 Generalized morphea, 223-224
 Geographical factors in epidemiology of PSS, 18
 Graft-versus-host disease, chronic, 236, 250-251
 Guttae morphea, 217
- HUTCHINSON-GILFORD syndrome, 246-247**
 Hydroxyproline content of skin, 64-65
 Hypertension, 168-169
- IMMUNOSUPPRESSIVE agents, in treatment of PSS, 289-294**
 Intimal thickness in kidney, 171
 Ischaemia, effect of on connective tissue, 197
- KELOID morphea, 225-226**
Kidney involvement in PSS, 167-184
 angiographic abnormalities in, 172-173
 clinical manifestations of, 168-170
 electron microscopic findings in, 171-172
 endothelial cell changes in, 171
 epidemiology of, 167
 histopathological features of, 170-172
 immunohistological findings in, 172
 management of, 271-274
 pathogenesis of, 173-178
 therapy, 178-179
- LARGE intestine in PSS, 124-126**
 Lichen sclerosis et atrophicus, 216-217
 Linear scleroderma, 220-221
 Liver in PSS, 126
 Localized forms of scleroderma, 8-9, 215-241
 and vitiligo, 226-227
 clinical features of, 217-228
 course and prognosis of, 233-235
 effect of colchicine on, 299-300
 epidemiology of, 215
 in children, 227-228
 laboratory findings in, 237-238
 management of, 238-239
 nomenclature and classification of, 216-217
 origin and pathogenesis of, 236-237
 pathology of, 228-233
 relation to PSS, 215-216
 ultrastructural studies of, 232-233
- MANAGEMENT of PSS, 263-302**
 Maximal oral aperture, 51, 53
 Melorheostosis, 257
 Microcirculation—
 clinical inspection, 84
 disorders of in PSS, 81-101
 functional abnormalities of, 90-91
 functional studies of, 84-85
 in vivo microscopy, 83-84
 in vivo observations and histopathological data, relationship between, 93-94
 morphological abnormalities of, 85-90
 Microvascular bed, definition of, 81-82
 Microvascular disturbances, treatment of, 96-97
 Microvasculature in the pathogenesis of scleroderma, 94-96
 Mixed connective tissue disease (MCTD), 5, 104, 110-111
- Morphea—**
 bullous, 226
 generalized, 223-224
 guttate, 217
 keloid (nodular), 225-226
 plaque-like, 217
 subcutaneous, 224-225
 Muscle biopsy, 107-110
 Musculoskeletal system, management of, 267-268
 Myocardial involvement, 132-141
 Myocardial lesions—
 clinical correlates of, 138
 pathogenesis of, 133-138
- NATURAL history of PSS, 19-22**
 Non-collagenous protein, 197-198
- OCCUPATIONAL factors in PSS, 18**
 Occupational pseudosclerodermas, 256-257
 Oesophagus in PSS, 115-120
 clinical features of, 115-116
 complications of, course and prognosis, 119
 diagnostic procedures in, 116-118
 pathology and pathophysiology of, 118-119
 treatment of, 119-120, 268
 Overlap syndromes, muscle involvement in, 110
- D-PENICILLAMINE, in treatment of PSS, 97, 277-288**
 efficacy of, 279, 280-283
 principles of, 278-280
 side effects of, 283-285

- Pericardial disease, 141
- Pharmacological agents in management of PSS, 264, 265-266
- Phenylketonuria, 75, 252-253
- Photoelectric plethysmography, 84
- Plaque-like morphea, 217
- Polymyositis-dermatomyositis (PM/DM), 18, 29, 30, 32, 36-37, 38, 103-105, 109-111
- Porphyria cutanea tarda, 251-252
- Procollagen, 186, 190, 192-195
- Progeria, 246-248
- Proteinuria, 168
- Pseudoscleroderma, 10, 11, 243-261
 - occupational, 256-257
- Pulmonary function, 157-163
- Pulmonary hypertension, 141-145, 156-157
- Pulmonary involvement in PSS, 151-166
 - clinical features of, 152-153
 - effect of chlorambucil on, 294
 - effect of D-penicillamine on, 282
 - management of, 270
 - pathological findings, 154-156
 - roentgenographic aspects of, 153-154
- Purine antimetabolites, 293
- RACE-SPECIFIC incidence and mortality in PSS, 16-18
- Raynaud's phenomenon, 7, 8, 15, 30, 94-96, 246, 249
 - management of, 266-267
 - cytogenetic observations on, 202-205
- Relation between localized and progressive systemic sclerosis, 215-217
- Renal blood flow, reduction of, 176
- Renal disease—
 - acute, 170-171
 - chronic, 171
- Renal system—
 - effect of colchicine on, 283
 - management of, 271-274
- Renal transplantation in PSS, 179
- Renin-angiotensin system in renal disease, 177-178
- Roentgenographic aspects in pulmonary involvement, 153-154
- SARALASIN, 272
- Scleroderma, 243-244
- Scleroderma—
 - evolution of, 49-54
 - histological changes in, 58-61
 - microvasculature in the pathogenesis of, 94-96
- Scleroderma Criteria Cooperative Study (SCCS), method and preliminary results of, 27-48
 - materials and methods, 29-36
 - preliminary preparations, 28-29
 - results, 36-43
- Scleroderma-like conditions, chemical-induced, 9
- Scleroderma *en coup de sabre*, 6, 217, 222
- Scleroderma, localized—see Localized forms of scleroderma
- Sclerodermatomyositis, 5
- Sclerodermatous skin changes, classification of disorders with, 15
- Scleromyxoedema, 253-255
- Serum muscle enzymes, 104-105
- Sex-specific incidence and mortality in PSS, 16-18
- Skeletal muscle involvement in PSS, 103-113
 - clinical course of, 110-111
 - historical note, 103-104
 - laboratory data, 104-110
 - management of, 267-268
 - physical examination in, 104
 - symptoms of, 104
 - therapy in, 110-111
- Skin—
 - effect of chlorambucil on, 294
 - effect of D-penicillamine on, 280-281
 - management of, 267
- Skin biopsies—
 - chemical analysis of—
 - hydroxyproline content, 64-65
 - water content, 64
 - weights of, 71, 72, 73, 75
 - changes in, 65-66
- Skin blood vessels, examination of, 83-84
- Skin thickening—
 - pathogenesis of, 66-76
 - symmetry of, 63-64
- Skin thickness, 61-63
- Small intestine in PSS, 120-124
 - clinical features, 120-122
 - complications, course and prognosis, 123
 - pathology and pathophysiology, 122-123
 - treatment, 123-124
- Smooth muscle cells in kidney, 171
- Stomach in PSS, 120
- Study design of SCCS, 29-30
- Subcutaneous morphea, 224-225
- Survival studies in PSS, 19-22
- Systemic lupus erythematosus (SLE), 16, 17, 18, 19, 30, 36-38
- TELANGIECTASES, 43, 52, 93
 - relationship with microvascular abnormalities, 91-93
- Teptotide, 272
- Thibierge-Weissenbach syndrome, 7, 58
- Thrombosis, 173-176
- URINE creatine and creatinine, 106

VENOUS occlusion plethysmography, 84
Vinyl chloride, 9
Viral infection, possible cause of
 chromosome damage, 208-209

Vitiligo, localized scleroderma and,
 226-227

WERNER's disease, 248-249



Index

Note: Page numbers of article titles are in **bold face type**.

ANALGESICS, 354

Ankylosing spondylitis, 704

see also under names of specific drugs

Anti-inflammatory drugs, classification of, 354-356

Aspirin, 499-539

absorption, distribution and excretion, 500-508

anti-inflammatory effects, 513-516

antipyretic effects, 513

aspirin allergy, 517-519

chemistry, 499

drug interactions, 516-517

effects on blood and blood coagulation, 510-513

history, 500

immunological effects, 510

metabolic and endocrine effects, 508-509

mixtures in common use, 503-504

newer salicylate preparations, 523-524

preparations in common use, 502

Azapropazone, 465-480

adverse reactions, 476-477

chemistry, 465-466

dosage and administration, 477-478

indications, 473-474

gout, 474

OA, 474

RA, 473-474

shoulder pain, 474

pharmacokinetics and metabolism, 469-470

pharmacological profile, 466-469

safety and tolerance, 474-475

toxicity, 471-473

BENOXAPROFEN, 398-410

chemistry, 399

effect on GI bleeding, 401-403

effectiveness in man, 403-406

in vitro effects, 400

metabolism in man, 401

pharmacology and toxicology, 399-400

Bone, Paget's disease of, *see* Paget's disease of bone, drug treatment of

CALCIFIC peri-arthritis, drug treatment of, 704-705

Chemistry, *see* under names of specific drugs

Chrysotherapy in RA, 631-640

dosage, 633-634

indications and contraindications, 638-639

pharmacology, 631-633

toxic effects, 634-637

Classification of anti-rheumatic drugs, 353-357

Clinical studies, *see* under names of specific drugs

DENTAL pain, use of diflunisal, 718

Diclofenac sodium, *see* Voltarol

Diflunisal, 707-731

adverse reactions, 722-726

chemistry, 707-708

clinical actions, 715-722

contraindications, 728

dosage, 728

indications, 728

interactions, 722

non-responders, 721-722

ototoxicity, 727

pharmacokinetics and metabolism, 713-715

pharmacology, 708-712

special safety studies, 726

toxicology, 712-713

Drug treatment, choice of in RA and other rheumatic diseases, 697-706

FAMILIAL Mediterranean fever, drug treatment of, 705

Fenoprofen, 393-398

chemistry, 393-394

pre-clinical pharmacology, 394-395

studies related to safety, 395-397

trials in osteoarthritis, 397-398

Flurbiprofen, 359-379

adverse reactions, 375

chemistry, 359-360

clinical actions, 371-374

- Flurbiprofen** (*contd.*)
 clinical uses, 376
 drug interactions, 373-374
 gastrointestinal tolerance, 374
 general pharmacology, 364-365
 mechanisms in action, 363-364
 pharmacokinetics and metabolism in man, 367-368
 specific pharmacology, 361-362
 toxicology, 365-366
- GOUT**, drug treatment of, **657-672**
 acute gouty arthritis, 659-662
 associated conditions, management of, 668-669
 colchicine, 662-664
 idiopathic hyperuricaemia, 669-670
 inhibitor of urate biosynthesis, 666-668
 prevention of progression of degenerative changes in articular and non-articular tissues, 662-668
 uricosuric agents, 664-666
- IBUPROFEN**, **359-379**
 adverse reactions, 374-375
 chemistry, 359
 clinical actions, 368-371
 clinical uses, 376
 drug interactions, 371
 gastrointestinal tolerance, 374
 general pharmacology, 364
 mechanisms of action, 362-363
 pharmacokinetics and metabolism in man, 366-367
 specific pharmacology, 360-361
 toxicology, 365
- Indomethacin**, **541-552**
 adverse reactions, 547-548
 chemistry and pharmacology, 541-543
 clinical actions, 544-547
 acute musculoskeletal disorders, 546
 ankylosing spondylitis, 545
 gout, 545-546
 OA, 544
 RA, 544-545
 clinical use, 548-550
 dosage, 550
 drug interactions, 549-550
 pharmacokinetics, 543
- JUVENILE arthritis**, drug treatment of, 703
- KETOPROFEN**, **381-391**
 biological tolerance, 387
 clinical tolerance, 385-387
 evaluation of activity in clinical practice, 383-385
 ankylosing spondylitis, 384
 gout, 384
 OA of hip and knee, 384
 RA, 383-384
 in animal pharmacology, 381
 metabolism and pharmacokinetics in man, 382-383
 mode of action, 381-382
 open studies, 385
- LEVAMISOLE**, **603-629**
 adverse reactions, 618
 chemistry, 604-605
 clinical actions, 611-618
 RA, 611-617
 biological effects, 614-615
 clinical effects, 611-614
 factors influencing responsiveness, 617
 immunological effects, 615-617
 other rheumatic diseases, 618
 contraindications, 623
 dosage, 622
 pharmacokinetics, 610-611
 pharmacology, 605-610
 toxicology, 610
 use, 622-624
- Low back pain**, use of diflunisal, 719
- Lupus erythematosus**, systemic, *see* Systemic lupus erythematosus
- MALIGNANT disease**, pain and the use of diflunisal, 719
- Metabolism**, *see under names of specific drugs*
- NAPROXEN**, **411-426**
 chemistry, 411-412
 drug interactions, 416-417
 pharmacokinetics and metabolism, 415-416
 pharmacology, 412-414
 therapeutic trials, 417-421
 toxicology, 414-415
- Non-steroidal anti-inflammatory drugs**, classification of, 354-355
- OSTEITIS deformans**, *see* Paget's disease of bone
- Osteoarthritis**, drug treatment of, 702-703
see also under names of specific drugs
- PAGET's disease of bone**, drug treatment of, **673-695**
 analgetics, 677
 biochemical features, 674-675
 calcitonins, 677-683
 combined treatment with diphosphonates, 688-689
 cause, 674
 clinical features, 675

- Paget's disease of bone (contd.)**
diphosphonates, 683-689
drug treatment, 676-677
histological features, 674
indications, 676-677
mithramycin, 689-690
nature of Paget's disease, 673-677
occurrence, 673-674
radiology and scintigraphy, 674
treatment, other aspects of, 691-693
- Palindromic rheumatism, drug treatment of, 704**
- Penicillamine, 569-601**
adverse effects, 587-593
chemistry, 571-572
comparison with other drugs, 586
dosage, 593-594
drug interactions, 592-593
effects on animal models of RA, 576-577
factors affecting response, 586-587
historical development, 569-570
indications, 593
pharmacokinetics, 577-580
pharmacology, 572-576
therapeutic role, 580-586
 cystinuria, 580
 juvenile chronic polyarthritis, 585
 palindromic rheumatism, 585
 progressive systemic sclerosis, 585-586
 RA, 580-585
 seronegative polyarthritis, 585
 Wilson's disease, 580
toxicology, 577
use in RA, 593-595
- Pharmacokinetics, see under names of specific drugs**
- Pharmacology, see under names of specific drugs**
- Polymyalgia rheumatica, drug treatment of, 704**
- Postoperative pain, use of diflunisal, 718-719**
- Post-traumatic pain, use of diflunisal, 719**
- Psoriatic arthropathy, drug treatment of, 703-704**
- REITER's disease, drug treatment of, 704-705**
- Rheumatoid arthritis and other rheumatic diseases, drug treatment of, 697-706**
acute calcific periarthritis, 704-705
ankylosing spondylitis, 704
conditions requiring intra-articular or local steroid therapy, 705
familial Mediterranean fever, 705
juvenile arthritis, 703
osteoarthritis, 702-703
palindromic rheumatism, 704
polymyalgia rheumatica, 704
psoriatic arthropathy, 703-704
RA, 697-702
 phase I: relief of symptoms, 700
 phase II: control of the disease, 700-702
Reiter's disease, 704-705
 see also under names of specific drugs
- SALICYLATES, 499-539**
absorption, distribution and excretion, 500-508
anti-inflammatory effects, 513-516
antipyretic effects, 513
aspirin allergy, 517-519
aspirin and the GI tract, 519-523
chemistry, 499
drug interactions with aspirin, 516-517
effects on blood and blood coagulation, 510-513
history, 500
immunological effects, 510
metabolic and endocrine effects, 508-509
newer salicylate preparations, 523-524
preparations in common use, 502
- SLE, see Systemic lupus erythematosus**
- Sports injuries, drug treatment of, 705**
- Sulindac, 553-568**
adverse effects, 563-565
chemistry and pharmacology, 553-555
clinical actions, 557-562
 acute gout, 560
 acute painful shoulder, 559-560
 ankylosing spondylitis, 561
 OA, 557-559
 RA, 561-562
- Systemic lupus erythematosus, treatment of, 641-655**
adverse drug reactions and allergies, 642-648
 antimalarials, 645-646
 aspirin, 643-644
 corticosteroids, 646-648
 immunosuppressive agents, 648
 NSAIDs, 644
cyclosporin A, 651
levamisole, 649-651
monitoring disease activity, 651-652
prostaglandin E, 651
pulse steroid therapy, 648-649
thoracic duct drainage, 649
- TOLMETIN sodium, 481-497**
clinical use, 490-493
 ankylosing spondylitis, 493
 non-articular rheumatism and soft tissue disease, 493
OA, 493
RA, 490-493

Tolmetin sodium (contd.)

- dosage and administration, 494-495
- drug interactions, 494
- non-articular rheumatism and soft tissue diseases, 486-487
- OA, 486
- pharmacokinetics, 490
- pharmacology, 488-490
- RA, 484-486
 - juvenile, 485-486
- untoward interactions, 494


Toxicology, see under names of specific drugs**VOLTAROL, 427-464**

- adverse reactions, 459-460
- blood coagulation factors and, 441-442
- clinical studies in ankylosing spondylitis, 451-452
- clinical studies in OA, 448-451
- clinical studies in RA, 444-447
- clinical trials, 452-455

OA, 454**RA, 453-454**

- drug comparisons, 444-450
- drug interactions, 439-450, 461
- effect on binding of L-tryptophan to plasma proteins, 442-443
- effects of diclofenac sodium in the human GI tract, 443-444
- laboratory studies of haemopoietic, hepatic and renal function, 457-458
- long-term studies in rheumatic diseases, 455-457
- OA, 456
- RA, 455-456
- pharmacokinetic studies in elderly subjects, 440-441
- pharmacokinetic studies in patients in renal failure, 441
- pharmacokinetics, metabolism and metabolites, 433-440
- pharmacology, 429-431
- pharmacology of metabolites, 431-433
- toxicity, 433





Index

Note: Page numbers of article titles are in **bold face type**.

- AB ARTICULAR gout, 810-811
 Adventitious bursae, 886
 Angiography, value of in temporal arteritis, 785-786
 Ankle, acute capsular strains of, 934-935
 Ankylosing spondylitis, enthesitis in, 865
 Anterior tibial tunnel syndrome, 952
 Anti-inflammatory agents, in treatment of soft tissue trauma, 929-930
 Arthropathies, metabolic, 866-869
- BAKER's cyst, 897
 Bicipital tendinitis, 895
 Bursae—
 'adventitious', 886
 anatomical background, 883-885
 and bursitis, 883-899
 chronic non-infectious inflammatory disease of, 889
 development and normal structure of, 885-886
 historical background, 883-885
 iliopsoas, 896
 iliopsoas, 896
 infection of, 886-887
 antibiotic-induced candidaemia, 887
 brucellar, 887
 septic, 886
 sporotrichosis, 887
 infrapatellar, 897
 popliteal, 897
 posterior gastrocnemiosemimembranosus, 897
 pseudotumoral lesions of, 889
 sub-Achilles, 897
 subcutaneous prepatellar, 897
 and tendons, and tendon sheaths, lesions of, 883-925
 Bursitis—
 anserine, 897
 bicipital, 895
 calcific, 888
 subacromial, 888
 in area of heel and foot, 897-899
 in area of hip joint, 895-897
 in knee region, 897
 of specific bursae, 889-899
 hyoid bursa, 889
 cervical interspinous bursa, 889-891
 lumbar interspinous bursa, 889-891
 scapular bursa, 893-894
 subacromial and upper limb bursae, 895
 septic, 886
 subsartorial, 897
 trochanteric, 896
- CALCERGV, 915
 Calcification, localized, of soft tissue, 818-819
 Calcific bursitis, 888
 subacromial, 888
 Calcific periarthritis, 813-818
 cause of inflammation in, 817
 clinical features of acute form of, 816
 localized variants of, 817
 Calcific tendinitis, and tenosynovitis, 915-917
 Calcifying collagenolysis, 815
 Calcinosi—
 generalized soft tissue, 813-815
 tumoral, 888
 'Calciophylaxis', 915
 Carpal tunnel syndrome, 942-946
 relationship with polymyalgia, 778
 Cerebrotendinous xanthomatosis, 915
 Cervical rib syndrome, 950-951
 Classification of soft tissue rheumatism, 739-742, 745-748
 Collagen, structure and synthesis of, 834-835
 Common peroneal nerve, entrapment of, 951-952
 Connective tissue diseases, associated with calcinosis, 814
 Cramp, 873-881
 at rest, 875
 causative factors, 877-878
 definition of, 873-878
 induced by treatment, 876-877
 chronic haemodialysis, 876
 morphine, 877

- Cramp—(contd)
 phenothiazine, 877
 saline diuretics, 876
 terbutaline, 877
 on effort, 874-875
 secondary to disease, 876
 treatment of, 878-881
- Crystal deposition disease—
 AB articular gout, 810-811
 and the soft tissues, 807-822
 formation of crystal deposits, 808-809
 hydroxyapatite deposition, 813-818
 in connective tissues, 808
 pyrophosphate crystals, 812-813
 urate deposition, 810-811
- Crystal-induced damage to soft tissues, 810
- Crystal-induced inflammation, pathogenesis of, 810
- Cytotoxic drugs, in pulmonary fibrosis, 843-844
- DEGENERATIVE bone and joint disease, relationship with enthesopathies, 864
- Dermatomyositis, calcinosis in, 814
- Diagnostic categories of soft tissue rheumatism, 746-748
- Drug-induced fibrosis, 842-843
- Dupuytren's disease, and contracture, 837-840
 aetiology of, 837-838
 clinical features of, 838
 histological changes in, 838-840
 prevalence, 837
- ENDORPHIN insufficiency, relative, fibrositis and, 830
- Entheses, 857-872
 anatomical characteristics of, 857-858
 changes of, with age, 859
 functional characteristics of, 858-859
 pathological changes of, 859
- Enthesopathy, 857-872
 aetiopathogenesis of, 860
 causing change in function, 860-861
 clinical manifestations of, 861
 enthesopathic component in inflammatory rheumatic disease, 865-866
 relationship with degenerative bone and joint diseases, 864
 relationship with periarthritis, 864-865
 treatment of, 869-870
 x-ray manifestations of, 861
- Entrapment neuropathies, 941-955
- Epidemiology of soft tissue rheumatism, 743-753
 localized forms of rheumatism, 745
 regional differences in symptom description, 744-745
- Ethosuximide, in production of fibrosis, 843
- Extra-articular calcification, 813-818
- FAMILIAL beta-hyperlipoproteinaemia, 914-915
- Fascia, deep, trauma to, 927
- Fasciitis—
 a discrete entity?, 835
 anatomical considerations of, 833
 and fibrosis, 833-855
 eosinophilic, 849
 nodular, 836-837
 pseudosarcomatous, 836-837
- Fibrosis—
 drug-induced, 842-843
 ethosuximide, 843
 methysergide, 842
 practolol, 842-843
 fasciitis and, 833-855
 idiopathic, 840-842
 inflammation and, 833-834
 mediastinal, 841-842
 retroperitoneal, 841
- Fibrositis—
 as a disorder of pain modulation, 823-832
 as a pain amplification syndrome, 830
 classification of, 826-829
 deep hyperalgesia in, 829
 management of fibrositic rheumatoid patient, 830-831
 primary, 826-827
 referred pain in, 829
 relative endorphin insufficiency and, 827-829
 sleep disturbance associated with, 827-829
 therapy of, 831-832
- GARGOYLISM, 911
- Generalized rheumatism, polymyalgia rheumatica, and its differential diagnosis, 775-795
- Gout, 911-914
- HAEMOCHROMATOSIS, 912
- Health service, utilization of by patients, 748-751
- Heredo-familial vascular and articular calcification, 815
- Hexamethonium, in pulmonary fibrosis, 843
- Hydroxyapatite crystal deposition, 813-817
 in tendons, 915-917
- Hyoid bursa, bursitis of, 889
- Hyperlipidaemias, 818
- IDIOPATHIC fibrosis, 840-842
 mediastinal fibrosis, 841-842
 Peyronie's disease, 840-841
 retroperitoneal fibrosis, 841
- Iliopsoas bursa, 896

- Incapacity for work, due to soft tissue rheumatism, 749-750
- Infective tenosynovitis, 907
- Inflammatory rheumatic diseases, enthesopathic component in, 865-866
- Interspinous bursae, 889-891
- JOINT diseases, in polymyalgia rheumatica, 777
- KNEE, ligamentous injuries of, 933-934
- LIGAMENTS, trauma to, 927, 930
- ankle, acute capsular strains, 934-935
- complete tear, 932
- partial tear, 932
- posterior cruciate, 933-934
- shoulder—
- dislocation of, 932-933
- subluxation of, 933
- sprains of knee ligament, 933
- Lipocalcinosis granulomatosis, 815
- Local forms of rheumatism, 745
- Localized classification of soft tissue rheumatism, 815-819
- MEASUREMENT of pain, 756-769
- Median nerve, compression of, 942-946
- Meniscus, tearing of, 935-936
- Meralgia paraesthetica, 953
- Metabolic arthropathies, 866-869
- Metabolic tendinopathies, 911-914
- Methysergide, in production of fibrosis, 842
- Morquio's syndrome, 912
- Morton's metatarsalgia, 953-954
- Muscle—
- injuries to, 936-938
- trauma to, 927
- Myositis ossificans progressiva, 815
- NEUROPATHIES, entrapment, 941-955
- Nitrofurantoin, in pulmonary fibrosis, 844
- Nodular fasciitis, 836-837
- diagnosis of, 836-837
- management of, 836-837
- pathology of, 836
- Nodular tenosynovitis, localized, 914
- OCHRONOSIS, 915
- Osteoarthritis, and polymyalgia rheumatica, 777-778
- PAIN—
- as a condition, 755
- as a parameter, 756-769
- elicited, 756
- spontaneous, 756-769
- as a symptom, 755-756
- management of, 755
- Pain Amplification Syndrome, 823
- fibrositis as a, 830
- Pain modulation, 'fibrositis' as a disorder of, 823-832
- Pain perception threshold, 755-773
- determination of by measurement of noxious stimulus and response to it, 764-769
- Pain tolerance threshold—
- and pain perception threshold, clinical and experimental studies, 755-773
- deep pain, methods of eliciting, 758
- intra-arterial injections, 758
- intra-articular injections, 758
- pressure devices, 758
- determination of, 757-761
- skin pain, determination of tolerance to, 757
- blister technique, 758
- bradykinin, intradermal injection of, 758
- electrical stimulation, 757, 761
- histamine, intradermal injection of, 758
- hot-plate application, 757
- infra-red application, 757
- prostaglandin, intradermal injection of, 758
- tourniquet technique, 758, 761
- Periarthroses, relationship with enthesopathies, 864-865
- Pigmented villonodular tenosynovitis, 914
- Polymyalgia rheumatica—
- abnormal laboratory test results in, 760-781
- plasma viscosity, 780
- raised ESR, 780
- aetiology of, 781-782
- age-group affected, 776
- characteristics of, 776-780
- delays in diagnosis of, 779-780
- differential diagnosis of, 775-795
- bone disease—
- osteomalacia, 789
- osteoporosis, 789
- Paget's disease, 789
- senile hyperostotic ankylosis of the spine, 789
- infection antedating, 789
- joint diseases—
- osteoarthritis, 790
- rheumatoid arthritis, 790
- systemic lupus erythematosus, 790
- muscle disease, 791
- neoplastic disease, 790-791
- other diseases, 791
- genetic factors and familial aggregation, 782
- incidence of, 776
- pathogenesis of, 781-782
- symptoms and signs of—

- Polymyalgia rheumatica—(contd)
 associated with liver, 779
 carpal tunnel syndrome, 778
 general health, 779
 muscle symptoms, 778–779
 synovitis, 777–778
 temporal angiography for, 785
 treatment, 786–788
 dose of corticosteroid, 786–787
 duration of, 787
 side effects of, 787–788
 Practolol, in production of fibrosis, 842–843
 Proctalgia fugax, 873
 Progressive systemic sclerosis, 847–849
 Pseudosarcomatous fasciitis, 836–837
 diagnosis of, 836–837
 management of, 836–837
 pathology of, 836
 Pseudotumoral lesions of the bursae, 889
 Psoriatic arthritis, and calcaneal enthesitis, 866
 Psychogalvanic skin reflex (PSR), 766–769
 Psychogenic rheumatism, 797–805
 symptoms of—
 benign dorsalgia, 799
 cervicocranial, 800
 coccydynia, 801
 nocturnal acroparaesthesias, 800–801
 pain in the xiphisternum, 801
 restless legs, 801
 treatment of, 803–805
 Psychogenic syndromes associated with
 organic disease, 802
 psychological changes in, 802
 Pulmonary fibrosis, drug-induced, 843–844
 PVC, disease associated with manufacture of,
 844–847
 Pyrophosphate crystal deposition, 812–813

 RADIAL nerve, entrapment of, 949–950
 Raynaud's phenomenon, and dermal thickening,
 in manufacture of PVC, 844–847
 Reiter's syndrome, and enthesitis of the calcaneum,
 806
 Rheumatoid arthritis, tenosynovitis and
 dinitis associated with, 907–911
 Rotator cuff lesion, 905

 SCAPULAR bursae, bursitis of, 893–894
 Sciatic plexus, entrapment lesions of, 951
 Scleroderma, 813, 814
 Shoulder, injury to ligaments, 932–933
 Sickness absence from work, due to soft tissue
 rheumatism, 750
 'Snapping scapula', 893–894
 Soft tissue calcification, generalized, 814–
 815
 Soft tissue injuries—
 anti-inflammatory agents in treatment of,
 929–930
 immediate care of, 928–929
 physical therapy of, 930
 Soft tissue rheumatism—
 concept and classification of, 739–742
 in the community, 743–753
 symptom experience of, 744
 Soft tissue trauma, sprains, strains, etc.,
 927–939
 biochemistry of, 929
 Sprains, 927, 932
 of the knee, 933
 Stenosis, of the tendon sheath, 903–905
 'Stitch', 873
 Strains, 927–939
 Subacromial bursa, 895
 Subdeltoid bursa, 895
 Sural nerve, entrapment lesions of, 953
 Systemic sclerosis, 847–849

 TARSAL tunnel syndrome, 952–953
 Temporal arteritis—
 history of, 775–776
 incidence of, 776
 pattern of, 785
 relationship with polymyalgia rheumatica,
 775, 784
 Tender points, in fibrositis, 824–826
 Tendinitis, 899–917
 associated with RA, 907–911
 bicipital, 895
 calcific, 915–917
 posterior tibial, 906
 Tendons, 899–917
 blood supply to, 900
 function of, 899
 rupture of, and repair, 901–903
 shoulder, lesions of, 905–907
 structure of, 899–900
 Tendon sheaths—
 infections of, 907
 tumorous conditions of, 914–915
 Tenosynovitis, 899–917
 associated with RA, 907–911
 calcific, 915–917
 peroneal, 906
 rotator cuff lesion, 905
 Thoracic outlet syndrome, 950–951
 Tophi, crystal, effects of, 811–812
 Trigger finger, 903–905
 Tumoral calcinosis, 815

 ULNAR nerve, entrapment of, 946–948
 Urate crystal deposition, 810–811

 VINYL CHLORIDE diseases, 844–847

EX

of,

tc.,

ca,